The Unmet Need: High Prevalence of ER+ Breast Cancer

2.1 Million

Total cases in the US, representing ~73% of all breast cancers1,2

~10%

are metastatic at diagnosis3

Up to 60%

of localized cancer relapse systematically3

27%

Survival Rate

For metastatic ER+ breast cancer3

Problem: ­

  • Majority of patients with breast cancer are treated with hormonal therapy, and all metastatic tumors develop resistance, and the only remaining treatment is toxic chemotherapy3

Market size: ­

  • Ibrance (CDK4/6 inhibitor): Worldwide sales of $4.96B in 2019
  • Piqray [phosphatidylinositol-3 kinase (PI3K) inhibitor]: Worldwide sales of $153 M in Q1/2 2020 following launch in 2019
1. United States Census Bureau. 2. American Cancer Society® Breast Cancer Facts & Figures 2019-2020. 3. Rozeboom B, et al. Am J Cancer Res. 2009; 9(12):2821-2831.

Series A Financing

Seeking $15 M Funding to Support Selected Studies ­

  • Randomized Phase 2 Study with Biomarker Validation ­
  • Two-Stage Simon Design Phase 2 Study of TTC 352 in ESR1-Mutated Breast Cancer
  • ­Phase 1B/2 of TTC-352 with PI3K Inhibitor or CDK4/6 Inhibitor in Partnership
for investors
 Save as PDF